Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma

Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma

Background: Concurrent treatment with BRAF inhibitors and palliative radiation therapy (RT) could be associated with increased toxicity, especially skin toxicity. Current Eastern Cooperative Oncology Group (ECOG) consensus guideline recommend ceasing BRAF inhibitors during RT. There is a lack of dat...

Full description

Bibliographic Details
Main Authors: Wei Wang, Jessica Louise Smith, Matteo Salvatore Carlino, Bryan Burmeister, Mark Blayne Pinkham, Gerald Blaise Fogarty, David Robert Harry Christie, Vanessa Estall, Mark Shackleton, Arthur Clements, Rory Wolfe, Le Thi Phuong Thao, Elizabeth Jane Paton, Victoria Steel, Narelle Catherine Williams
Format: Article
Language:English
Published: Elsevier 2021-09-01
Series:Clinical and Translational Radiation Oncology
Subjects:
Melanoma
Radiation therapy
BRAF inhibitors
MEK inhibitors
Dabrafenib
Trametinib
Online Access:http://www.sciencedirect.com/science/article/pii/S2405630821000744

Internet

http://www.sciencedirect.com/science/article/pii/S2405630821000744

Similar Items